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Introduction
Lichen sclerosus (LS), also known as ‘lichen
sclerosus et atrophicus’, is a chronic inflammatory
disease, affecting skin and mucosa, characterised by
autoimmune tissues atrophy. Every region of the
body can be affected, but both in men and women it
particularly occurs in genital areas, i.e. anogenital
region. The median age is about 50 years, although it
may be observed at any age, and children may be
affected too. The disease is more common in women
than men. In women, LS is, by far, the most frequent
vulvar dermatosis. The male form of LS has been
referred to as balanitis xerotica obliterans, correlating
with anatomic location, clinical appearance and his-
tological findings of this condition. The disease has
to be diagnosed, treated, and carefully followed-up,
as there is a definite, though small, risk of squamous
cell carcinoma development.
In this report, we describe the case of a 54-
years-old woman, who presented with recurrent cys-
titis, straguria and dysuria, secondary to urinary out-
flow obstruction due to LS. Diagnosis was very diffi-
cult because of the extremely localized lesion(1-6).
Case report
A 54-years-old woman was admitted to our
Department, in November 2010, for recurrent
cystitis. 
In 2005, she had been diagnosed with high
blood pressure, and treated with ACE-inhibitors. In
April 2010 she fractured her left wrist, and lesion
was treated by plaster. Since August 2010 she suf-
fered from recurrent cystitis (at least 4 episodes
during the last 3 months), with straguria and
dysuria, causing several admittances to citizen
emergency rooms and taking levofloxacin, fos-
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SUMMARY
Lichen sclerosus (LS), also known as ‘lichen sclerosus et atrophicus’, is an acquired, chronic, inflammatory, fibrotic and
atrophic disease, usually affecting skin, particularly genital region. It affects women, with a median age of 50 years. No etiological
factor is actually known, nevertheless several risk factors have been proposed, including genetic predisposition, trauma, infections,
and hormonal, metabolic and autoimmune diseases. Symptoms are deeply different: from mouth and/or anal/rectal dermatological
manifestations, to urological disorders, whose most common are stranguria and dysuria. Here we described a case of a woman,
affected by recurrent cystitis, stranguria and pelvic pain. Therefore, we reviewed etiological, clinical and histopathological aspects of
this uncommon and difficult to identify disease, especially respect to its urinary complications.
Key words: lichen sclerosus, recurrent cystitis, vulvar squamous cell carcinoma.
Received January 19, 2012; Accepted January 21, 2012
fomicin and others beta-lactam antibiotics, without
any benefit. In October 2010 her urine culture was
positive to Escherichia coli (1.000.000 CFU/ml),
sensitive to cefotaxime, ceftazidime, cotrimoxazole
and fosfomycin. In November 2010 she was admit-
ted to the Department of Emergency Medicine of
our University Hospital due to persistence of stran-
gury and dysuria. She was discharged with diagno-
sis of ‘abdominal pain in patient affected with
recurrent cystitis and high blood pressure’. During
hospitalization, she underwent gynecological and
urological examination, both negative, and to
abdominal basal computerized tomography (CT),
with evidence of liver angioma.
The same month, after few days, she was read-
mitted to our Department of Emergency Medicine
due to the persistence of the above mentioned
symptoms, associated with pollakiuria, urinary
urgency, sense of ipogastric and vaginal weight,
and urethral meatus burning, without any other
symptoms and/or signs implying others organs and
systems. Then she underwent surgical (which sug-
gested colonscopy) and gynaecological (negative)
examination, and abdominal basal CT, that showed
a colonic diverticular disease.
Therefore, she was transferred to our
Department for further investigation and appropri-
ate treatment. Nothing remarkable emerged from
physical examination, except for onychomycosis of
the fifth finger of the right foot, lower intensity of
the left common carotid pulse, murmur 2/6 Levine
heard over the mitral, aortic and tricuspid areas,
pain in epigastrium and lower abdominal quadrants.
The haematochemical and instrumental inves-
tigations, performed during hospitalization, were
not successful to define the exact nature and origin
of symptoms/signs that aimed the admission. The
patient underwent urological, gynaecological (com-
pleted with transvaginal ultrasound), gastroentero-
logical examinations, together with lower basal
abdomen CT (positive detection of Bence-Jones
protein in urine), cystography, cystoscopy, sigmoi-
doscopy (‘diverticulosis of the sigmoid colon’),
with substantially negative results.
Finally, a further gynecological examination,
afterward confirmed by a dermatological visit,
diagnosed the presence of a periurethral LS, with
partial obliteration of urethral meatus, which
explained the reported symptoms and the recent
history of recurrent cystitis, due to urinary outflow
obstruction. Then the patient was treated with
antibiotics (cotrimoxazole plus metronidazole, both
i.v. and orally), associated with topical steroid treat-
ment. Therefore, the patient improved and was dis-
charged with indication to periodical gynaecologi-
cal and dermatological follow-up to evaluate effects
of therapy and evolution of disease.
Discussion
LS is an acquired, chronic, inflammatory,
fibrotic and atrophic mucocutaneous disease, of
unknown aetiology. The median age is about 50
years, although it may be observed at any age, and
children may be affected too. It mainly occurs in
women, but its true epidemiology is, yet, not well
known, because affected patients may have no
symptoms, and those with symptoms may be too
frightened or embarrassed to seek help. However,
some studies demonstrated a female to male ratio of
10:1, others of 1:1, depending from examined pop-
ulation and diagnostic criteria(7,8). 
No clear etiological factor has been identified,
and there are conflicting evidences about genetic
factors (familial LS and association with class II
HLA DQ7, DQ8, DQ9 and interleukin 1 receptor
antagonist (IL-1ra) gene expression, which may be
associated with extension and severity of lesions)(9-
11) traumas (extragenital LS has been reported at
clothing fractioning sites and presence of Koebner
phenomenon may be founded at sites of lesion, so
trauma, injury and sexual abuse have been suggest-
ed as possible triggers)(12,13), infections (Borrelia
burgdorferi genome has been isolated from
lesions)(14), sex hormones metabolism abnormalities
(a reduction of dihydrotestosterone levels has been
demonstrated)(15), autoimmunity disorders (associa-
tion with vitiligo, alopecia areata, autoimmune thy-
roid disease and systemic lupus erythematosus;
moreover, IgG autoantibodies against extracellular
matrix protein 1 (ECM-1) have been detected in
67% of patients, even if they are not presumed to be
pathogenic)(16,17), together with connective tissue
alteration (increased elastase activity, loss of dermal
elastic tissue, increased glycosaminoglycan secre-
tion and absence of collagenasis)(18), and immunocy-
tological alterations (peripheral and lesional reduc-
tion of CD3 [all T cells] and CD4 [T helper cells]
count, evidence of T cell lesional activation, raise
of CD1a+ Langerhans cells in all histological phas-
es of LS, increased IL-6 immunoreactivity and p53
expression enhancement)(19-24). 
The disease primarily affects the anogenital
mucocutaneous area. In women, a characteristic
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vulvar, perineal and perianal pattern has been
likened to an eight or a keyhole, and may extend to
the medial surface of thigh. Contrariwise, men pre-
sent mainly involvement of the glans penis, where-
as anal localization is almost rare. Most of affected
women manifested vulvar intractable itching, sore-
ness and pain. Dysuria, dyspareunia, apareunia,
frigidity, reduced frequency of sexual intercourses,
anal itching, and pain on defecation are other com-
mon symptoms, but often the patients are complete-
ly asymptomatic.
Some patients have persistent, following treat-
ment, vulvar dysesthesia, indicating an associated
vulvodynia. This could be the basis of apparent
treatment failure cases. In males, first presenting
symptom of this disease can be easily phimosis.
Both in females and males, extragenital involve-
ment is often asymptomatic, whereas, sometimes,
severe pruritus can be associated. It may occur in 2-
15% of affected and range from a single papule to a
widespread outbreak, although the latter is unusual.
The most common sites are neck, shoulders, wrist
and sub mammary area. Rarely it may be affected
scalp, oral cavity, palms and soles too.
Generally, genital lesions features are pallor,
hyperkeratosis and atrophy (mainly affecting labia
minora and inner labia majora); sometimes telang-
iectasia, purpura, erosions, tender fissures in the
labial sulci and perianal area and, rarely, haemor-
rhagic blisters may occurs too. Extragenital lesions
appear as pale macule or papule, which may coa-
lesce into plaques, and rarely itch. LS may also
cause anatomical changes, i.e. fusion of labia mino-
ra, leading to obliteration of interlabial sulci, and
adhesion of mucosa overlying clitoris and urethral
opening, which can lead to phimosis and obstruc-
tion of urinary outflow(25-30).
Morphology of LS is usually characteristic
and a clinical diagnosis can be made in most
women via examination of anogenital mucocuta-
neous area. Diagnosis must be histologically con-
firmed, without biopsy from eroded skin if possible.
As a matter of fact, histologic features are more
specific than clinical ones. Optical microscopy usu-
ally shows variable epithelial thinning, with ‘loss of
network ridging’, and, sometimes, massive overly-
ing keratosis can be detected. Hydropic degenera-
tion of the basal layer is often the most striking fea-
tures, but typical features of histological framework
are edema and homogenization of collagen in over-
lying dermis, associated with elastic fibres reduc-
tion and monocytic, lymphocytic and mast cells
infiltration. This inflammatory infiltrate seems to
reflect LS clinical course, which is a chronic relaps-
ing remitting one(31,32).
It’s also important considering possibility of
coexistence of Candida and bacterial infection in
patients with LS undertaking appropriate micro-
scopically and cultural investigations, if clinically
indicated(33).
Risk of malignant transformation may be due
to scratching-connected epithelial hyperplasia.
Some, recent studies noticed possibility of LS evo-
lution to squamous cell carcinoma in 4-5% of
affected women. The real extent of neoplastic trans-
formation in diagnosed and treated LS in not
known, nevertheless it is considered appropriate to
carry out a long-term follow-up. Furthermore,
immunocytochemical studies show aberrant p53
expression in lesion, as well as, by PCR, it is possi-
ble to isolate the genome of human papilloma
virus(34,35).
Differential diagnosis between LS and lichen
planus (LP) is usually simple, both clinically and
histologically, although it can be difficult on
mucosa sites. Evidence pointed out existence of
LS/LP overlap syndrome and it has been hypothe-
sized these conditions may represent transitional
stages of a unique disease, rather than coexistence
of both(36). 
According to age and site of presentation,
several specialists, as paediatricians, gynaecolo-
gists, urologists, dermatologists, and internal medi-
cine physicians can manage LS. As in our case, this
leads to diagnostic difficulty and fragmented
approach, due to lacunose knowledge of the disease.
No curative therapy is actually known, and
only symptomatic treatments can be used. Bland
emollients, such as emulsifying ointment or aque-
ous cream, are safe and generally well tolerated.
Patient should be informed of necessity keeping
good anogenital hygiene, and should be advised to
wear cotton clothes and avoid little comfortable and
occlusive clothing. Corticosteroid ointments,
applied twice daily for 2-3 months, can provide
effective relief of symptoms in most patients, and
can be considered treatment milestones of anogeni-
tal LS. Furthermore, systemic steroid therapy can
be used for extensive mucocutaneous disease. In
addition to steroid, antibiotic therapy may be given,
both local and systemic, alone or in combination, if
a bacterial infection coexists, i.e. metronidazole.
Old therapies, based on local use of androgen
and/or progestin creams, have, nowadays, no more
Lichen sclerosus as a cause of recurrent cystitis... 21
useful evidence. As late, therapy with retinoid and
immunosuppressive drugs (cyclosporine and cal-
cineurin inhibitors) can be considered: first showed
excessive cutaneous irritation, the other having no
relevant percutaneous adsorption. There are no
more indications for surgery, except for surgical
separation of mucosa adhesions (phimosis or urine
flow obstruction), and vulvectomy if there are
unequivocal evidences of neoplastic progression.
Moreover, healed patients should be warned of pos-
sible LS resurgence, and advised to contact again
the physician at recurrence of symptoms and/or
lesions. Aforesaid reinforces, even more, the need
of long-term follow-up(37-42).
In conclusion, considering our patient, we can
explain its recurrent cystitis as induced by anatomi-
cal reduction of urinary outflow. Difficulties in
diagnosis were due to lack of typical
symptoms/signs of LS and physicians unfamiliarity
with the disease. As a matter of fact, if men usually
present phimosis, women easily might be totally
asymptomatic. So, LS should be considered in dif-
ferential diagnosis of recurrent cystitis, resistant to
antibiotic therapy, especially if young women with-
out any known associated risk factor (immunosup-
pression, diabetes, cystocele, uterine prolapse, uri-
nary or reproductive tract surgery, and risky sexual
behaviour) are the affected patients. Furthermore,
sequenced follow-up should be considered, both to
verify effectiveness of topical or systemic therapy,
to evaluate occasionally recurrence of the disease
and to exclude possible, even if extremely rare,
evolution to squamous cell carcinoma.
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